Molecular Cancer Therapeutics CTRC-AACR San Antonio Breast Cancer Symposium Bridging the Lab and the Clinic in Cancer Medicine
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jimeno, A.
Right arrow Articles by Hidalgo, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jimeno, A.
Right arrow Articles by Hidalgo, M.
Related Collections
Right arrow Clinical Research
Right arrow Clinical Research: Response Markers and Mechanisms
Mol Cancer Ther. 2006;5:787-796
© 2006 American Association for Cancer Research

Drug Development Series: Review

Molecular biomarkers: their increasing role in the diagnosis, characterization, and therapy guidance in pancreatic cancer

Antonio Jimeno and Manuel Hidalgo

Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, Maryland

Requests for reprints: Manuel Hidalgo, Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Room 1M88, 1650 Orleans Street, Baltimore, MD 21231-1000. Phone: 410-502-3850; Fax: 410-614-9006. E-mail: mhidalg1{at}jhmi.edu

Abstract

The rapidly expanding knowledge of the pathogenesis of pancreatic cancer at the molecular level is providing new targets for disease characterization, early diagnosis, and drug discovery and development. Gene mutation analysis has provided insight on the pathogenesis and progression from preinvasive lesions to invasive cancer. Gene and protein expression profiling has advanced our understanding of pancreatic ductal adenocarcinoma identifying genes that are highly expressed in pancreatic cancers, providing more insight into the clinicopathologic features of pancreatic cancer, and revealing novel features related to the process of tissue invasion by these tumors. The increasing knowledge of the pathway activation profile in pancreatic cancer is yielding new targets but also new markers to select patients and guide and predict therapy efficacy. The discovery of genetic factors of which the presence predisposes pancreatic cancer to successful targeting, such as the association of BRCA2/Fanconi anemia genes defects and sensitivity to mitomycin C, will eventually lead to a more individualized treatment approach. In summary, several decades of intensive research have originated multiple factors or biomarkers that are likely to be helpful in the diagnosis, characterization, and therapy selection of pancreatic cancer patients. A deep understanding of the relative relevance of each biomarker will be key to efficiently diagnose this disease and direct our patients towards the drugs more likely to be of benefit based on their particular profile. The development of new preclinical models is of paramount importance to achieve these goals. [Mol Cancer Ther 2006;5(4):787–96]


Footnotes

1 Rubio-Viqueira et al., in press.

Received 1/ 4/06; revised 2/ 6/06; accepted 2/21/06.




This article has been cited by other articles:


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
N. Y. Jiang, B. A. Woda, B. F. Banner, G. F. Whalen, K. A. Dresser, and D. Lu
Sp1, a New Biomarker That Identifies a Subset of Aggressive Pancreatic Ductal Adenocarcinoma
Cancer Epidemiol. Biomarkers Prev., July 1, 2008; 17(7): 1648 - 1652.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
W. Liu, D. A. Bloom, W. G. Cance, E. V. Kurenova, V. M. Golubovskaya, and S. N. Hochwald
FAK and IGF-IR interact to provide survival signals in human pancreatic adenocarcinoma cells
Carcinogenesis, June 1, 2008; 29(6): 1096 - 1107.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
T. Egami, K. Ohuchida, K. Mizumoto, M. Onimaru, H. Toma, S. Nishio, E. Nagai, K. Matsumoto, T. Nakamura, and M. Tanaka
Radiation Enhances Adenoviral Gene Therapy in Pancreatic Cancer via Activation of Cytomegalovirus Promoter and Increased Adenovirus Uptake
Clin. Cancer Res., March 15, 2008; 14(6): 1859 - 1867.
[Abstract] [Full Text] [PDF]


Home page
Ann. Surg. Oncol.Home page
T. Sasada, K. Azuma, T. Hirai, H. Hashida, M. Kanai, T. Yanagawa, and A. Takabayashi
Prognostic Significance of the Immediate Early Response Gene X-1 (IEX-1) Expression in Pancreatic Cancer
Ann. Surg. Oncol., February 1, 2008; 15(2): 609 - 617.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2006 by the American Association for Cancer Research.